Dyslipidemia is when the lipids in your blood are too high or too low. Estimates suggest that 53 percent of adults in the U.S. have lipid abnormalities. Lipids are a type of fat that make up the ...
CKD patients face higher CVD risk, with dyslipidemia differing from the general population, necessitating tailored lipid ...
The Gemini Study was a 14-week, open-label, non-comparative, office-based, multicenter trial to evaluate single-pill therapy in the treatment of concomitant hypertension and dyslipidemia. In addition ...
Dyslipidemia is when the lipids in your blood are too high or too low. Estimates suggest that 53 percent of adults in the U.S. have lipid abnormalities. Lipids are a type of fat that make up the ...
Abbott (Abbott Park, Ill.) and AstraZeneca (London, UK) have submitted a New Drug Application (NDA) for an investigational drug to treat mixed dyslipidemia. Pending approval of the NDA, the drug will ...
Please provide your email address to receive an email when new articles are posted on . Three phase 2 trials demonstrated the efficacy and safety of RNA interference therapy for the treatment of mixed ...
Atherosclerosis may be stopped if lipid screening and dyslipidemia intervention begin in adolescence
Importantly, lipid treatment intervention at the age of 17 years effectively stopped and reversed atherosclerosis progression. This study is a critical piece of evidence for the general population's ...
Obesity continues to become more common worldwide, despite the health risks and increased mortality posed by the diseases and conditions that accompany it (comorbidities). Although obesity’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback